File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of severe proliferative lupus nephritis: The current state

TitleTreatment of severe proliferative lupus nephritis: The current state
Authors
Mok, CCWong, RWSLai, KN
Issue Date2003
PublisherB M J Publishing Group. The Journal's web site is located at http://ard.bmjjournals.com/
Citation
Annals Of The Rheumatic Diseases, 2003, v. 62 n. 9, p. 799-804 How to Cite?
DOI: http://dx.doi.org/10.1136/ard.62.9.799
AbstractDespite the development of new modalities, cyclophosphamide (CYC) remains the preferred initial treatment for severe proliferative lupus nephritis. Controversies continue about the best route, dosage, and duration of CYC treatment. For recalcitrant disease, new immunosuppressive and immunomodulating agents, immunoablative high dose CYC, nucleoside analogues, apheresis, and the biological response modifiers can be considered.
Persistent Identifierhttp://hdl.handle.net/10722/45147
ISSN
0003-4967
2021 Impact Factor: 27.973
2020 SCImago Journal Rankings: 6.333
PubMed Central ID
PMC1754677
ISI Accession Number ID
WOS:000184792800003
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorMok, CCen_HK
dc.contributor.authorWong, RWSen_HK
dc.contributor.authorLai, KNen_HK
dc.date.accessioned2007-10-30T06:18:21Z-
dc.date.available2007-10-30T06:18:21Z-
dc.date.issued2003en_HK
dc.identifier.citationAnnals Of The Rheumatic Diseases, 2003, v. 62 n. 9, p. 799-804en_HK
dc.identifier.issn0003-4967en_HK
dc.identifier.urihttp://hdl.handle.net/10722/45147-
dc.description.abstractDespite the development of new modalities, cyclophosphamide (CYC) remains the preferred initial treatment for severe proliferative lupus nephritis. Controversies continue about the best route, dosage, and duration of CYC treatment. For recalcitrant disease, new immunosuppressive and immunomodulating agents, immunoablative high dose CYC, nucleoside analogues, apheresis, and the biological response modifiers can be considered.en_HK
dc.format.extent159356 bytes-
dc.format.extent1792 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherB M J Publishing Group. The Journal's web site is located at http://ard.bmjjournals.com/en_HK
dc.relation.ispartofAnnals of the Rheumatic Diseasesen_HK
dc.rightsAnnals of the Rheumatic Diseases: the EULAR journal. Copyright © B M J Publishing Group.en_HK
dc.subject.meshLupus Nephritis - drug therapyen_HK
dc.subject.meshBiological Response Modifiers - therapeutic useen_HK
dc.subject.meshCyclophosphamide - therapeutic useen_HK
dc.subject.meshDrug Administration Schedulexen_HK
dc.subject.meshImmunosuppressive Agents - therapeutic useen_HK
dc.titleTreatment of severe proliferative lupus nephritis: The current stateen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0003-4967&volume=62&issue=9&spage=799&epage=804&date=2003&atitle=Treatment+of+severe+proliferative+lupus+nephritis:+the+current+stateen_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1136/ard.62.9.799en_HK
dc.identifier.pmid12922948-
dc.identifier.pmcidPMC1754677-
dc.identifier.scopuseid_2-s2.0-0042887358en_HK
dc.identifier.hkuros87427-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0042887358&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume62en_HK
dc.identifier.issue9en_HK
dc.identifier.spage799en_HK
dc.identifier.epage804en_HK
dc.identifier.isiWOS:000184792800003-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridMok, CC=7102344226en_HK
dc.identifier.scopusauthoridWong, RWS=34875928200en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK
dc.identifier.issnl0003-4967-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats